Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1979 Oct;55(648):723–727. doi: 10.1136/pgmj.55.648.723

The delayed appearance of an antinuclear factor and the diagnosis of systemic lupus erythematosus in glomerulonephritis.

S A Cairns, E J Acheson, C L Corbett, S Dosa, N P Mallick, W Lawler, G Williams
PMCID: PMC2425745  PMID: 317153

Abstract

In 11 patients who presented with apparently idiopathic glomerular disease the antinuclear factor (ANF) was absent initially but was eventually detected during observation extending over 6 years. In 4 patients a diagnosis of systemic lupus erythematosus (SLE) has now been made and the disease treated. Of the remaining 7, 2 had conditions known to be associated with a positive ANF, and in 4, drug therapy induced the ANF. Clinical features, complement studies and measurement of anti-DNA antibody were of value in distinguishing those patients with SLE from the others.

Full text

PDF
723

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D. Drug-induced antinuclear antibodies and lupus syndromes. Drugs. 1976;12(1):69–77. doi: 10.2165/00003495-197612010-00003. [DOI] [PubMed] [Google Scholar]
  2. Baldwin D. S., Gluck M. C., Lowenstein J., Gallo G. R. Lupus nephritis. Clinical course as related to morphologic forms and their transitions. Am J Med. 1977 Jan;62(1):12–30. doi: 10.1016/0002-9343(77)90345-x. [DOI] [PubMed] [Google Scholar]
  3. Bartholomew B. A. Antinuclear antibody tests as a clinically selected screening procedure. Am J Clin Pathol. 1974 Apr;61(4):495–499. doi: 10.1093/ajcp/61.4.495. [DOI] [PubMed] [Google Scholar]
  4. Burnham T. K. Antinuclear antibodies in patients with malignancies. Lancet. 1972 Aug 26;2(7774):436–436. doi: 10.1016/s0140-6736(72)91842-9. [DOI] [PubMed] [Google Scholar]
  5. Cameron J. S., Lessof M. H., Ogg C. S., Williams B. D., Williams D. G. Disease activity in the nephritis of systemic lupus erythematosus in relation to serum complement concentrations. DNA-binding capacity and precipitating anti-DNA antibody. Clin Exp Immunol. 1976 Sep;25(3):418–427. [PMC free article] [PubMed] [Google Scholar]
  6. Cathcart E. S., Idelson B. A., Scheinberg M. A., Couser W. G. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet. 1976 Jan 24;1(7952):163–166. doi: 10.1016/s0140-6736(76)91272-1. [DOI] [PubMed] [Google Scholar]
  7. Cavallo T., Cameron W. R., Lapenas D. Immunopathology of early and clinically silent lupus nephropathy. Am J Pathol. 1977 Apr;87(1):1–18. [PMC free article] [PubMed] [Google Scholar]
  8. Cohen A. S., Canoso J. J. Criteria for the classification of systemic lupus erythematosus--status 1972. Arthritis Rheum. 1972 Sep-Oct;15(5):540–543. doi: 10.1002/art.1780150512. [DOI] [PubMed] [Google Scholar]
  9. Davis P., Atkins B., Josse R. G., Hughes G. R. Criteria for classification of S.L.E. Br Med J. 1973 Jul 14;3(5871):88–89. doi: 10.1136/bmj.3.5871.88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dosa S., Cairns S. A., Lawler W., Mallick N. P., Slotki I. N. The treatment of lupus nephritis by methyl prednisolone pulse therapy. Postgrad Med J. 1978 Sep;54(635):628–632. doi: 10.1136/pgmj.54.635.628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dujovne I., Pollak V. E., Pirani C. L., Dillard M. G. The distribution and character of glomerular deposits in systemic lupus erythematosus. Kidney Int. 1972 Jul;2(1):33–50. doi: 10.1038/ki.1972.67. [DOI] [PubMed] [Google Scholar]
  12. Elsas L. J., Hayslett J. P., Spargo B. H., Durant J. L., Rosenberg L. E. Wilson's disease with reversible renal tubular dysfunction. Correlation with proximal tubular ultrastructure. Ann Intern Med. 1971 Sep;75(3):427–433. doi: 10.7326/0003-4819-75-3-427. [DOI] [PubMed] [Google Scholar]
  13. Epstein W. V. Laboratory tests in rheumatic diseases. Med Clin North Am. 1977 Mar;61(2):377–387. doi: 10.1016/s0025-7125(16)31339-6. [DOI] [PubMed] [Google Scholar]
  14. Feltkamp T. E., Mees E. J., Nieuwenhuis M. G. Autoantibodies related to treatment with chlorthalidone and alpha-methyldopa. Acta Med Scand. 1970 Mar 3;187(3):219–223. doi: 10.1111/j.0954-6820.1970.tb02934.x. [DOI] [PubMed] [Google Scholar]
  15. Husain M., Neff J., Daily E., Townsend J., Lucas F. Antinuclear antibodies. Clinical significance of titers and fluorescence patterns. Am J Clin Pathol. 1974 Jan;61(1):59–65. doi: 10.1093/ajcp/61.1.59. [DOI] [PubMed] [Google Scholar]
  16. Koffler D., Agnello V., Carr R. I., Kunkel H. G. Variable patterns of immunoglobulin and complement deposition in the kidneys of patients with systemic lupus erythematosus. Am J Pathol. 1969 Sep;56(3):305–316. [PMC free article] [PubMed] [Google Scholar]
  17. Levinsky R. J., Cameron J. S., Soothill J. F. Serum immune complexes and disease activity in lupus nephritis. Lancet. 1977 Mar 12;1(8011):564–567. doi: 10.1016/s0140-6736(77)91998-5. [DOI] [PubMed] [Google Scholar]
  18. Lindstedt G., Lundberg P. A., Westberg G., Kaijser B. S.L.E. nephritis with positive tests for antibodies against native D.N.A. but negative tests for antinuclear antibodies. Lancet. 1977 Jul 16;2(8029):135–135. doi: 10.1016/s0140-6736(77)90140-4. [DOI] [PubMed] [Google Scholar]
  19. POLLAK V. E., PIRANI C. L., SCHWARTZ F. D. THE NATURAL HISTORY OF THE RENAL MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS. J Lab Clin Med. 1964 Apr;63:537–550. [PubMed] [Google Scholar]
  20. SIMENHOFF M. L., MERRILL J. P. THE SPECTRUM OF LUPUS NEPHRITIS. Nephron. 1964;1:348–375. doi: 10.1159/000179349. [DOI] [PubMed] [Google Scholar]
  21. Serum and urine paraprotein and filling defects in the spleen. Am J Med. 1976 Apr;60(4):531–540. doi: 10.1016/0002-9343(76)90720-8. [DOI] [PubMed] [Google Scholar]
  22. Svec K. H., Veit B. C. Age-related antinuclear factors: immunologic characteristics and associated clinical aspects. Arthritis Rheum. 1967 Dec;10(6):509–516. doi: 10.1002/art.1780100604. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES